Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obta...

Source: Respiratory Research - May 11, 2021 Category: Respiratory Medicine Authors: Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han and Xueyan Zhang Tags: Research Source Type: research